Attached files

file filename
EX-99.1 - PRESENTATION - Rezolute, Inc.ex99_1.htm
EX-99.2 - PRESS RELEASE OF ANTRIABIO, INC. DATED JUNE 8, 2015 - Rezolute, Inc.ex99_2.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2015

ANTRIABIO, INC.
(Name of registrant in its charter)

Delaware
000-54495
27-3440894
(State or jurisdiction
(Commission File
(IRS Employer
of incorporation or
Number)
Identification No.) 
organization) 
   

1450 Infinite Drive
Louisville, CO 80027
 (Address of principal executive offices)

(303) 222-2128
 (Registrant's telephone number)

________________________
 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 


Item 7.01. Regulation FD Disclosure.
 
On June 6, 2015, Dr. Brian Roberts gave an oral presentation at the American Diabetes Association 75th Scientific Sessions® in Boston (the “Presentation”) which is attached hereto herein as Exhibit 99.1.  On June 8, 2015, we issued the press release attached hereto as Exhibit 99.2 announcing the Presentation and providing a link to the Presentation in the press release.  In accordance with General Instruction B.2 of Form 8-K, the information set forth herein, the Presentation and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.  The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits
 
EXHIBIT
DESCRIPTION
99.1
Presentation **
99.2
Press Release of AntriaBio, Inc. dated June 8, 2015 **

** The following exhibits relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.
 
 
 
 

 

2
 

 


 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  
ANTRIABIO, INC.
  
 
  
  
 
  
DATE:  June 8, 2015
By:
/s/ Morgan Fields         
   
Morgan Fields
Chief Accounting Officer

 

 
 
 
 
 
 
3
 

 


 
EXHIBIT INDEX
 
EXHIBIT
DESCRIPTION
99.1
Presentation **
99.2
Press Release of AntriaBio, Inc. dated June 8, 2015 **

** The following exhibits relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

 


 
 
 
4